Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Short Attention Span? Shire Cited Again For Out-Of-Bounds ADHD Promotion

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA says that Intuniv patient materials claimed it treats such non-ADHD behavioral problems as temper outbursts.

You may also be interested in...



Jazz Buys Compliance Trouble With FazaClo Acquisition

The schizophrenia drug’s previous owner, Azur Pharma, produced a patient brochure that drew a warning letter FDA’s Office of Prescription Drug Promotion.

FDA Repulsed By Shire's Magnetic Promotion Of Vyvanse

DDMAC warning letter objects to a promotional magnet that obscures risk information; Bad Ad program draws attention to the tchotchke, which Shire stopped distributing in 2008.

FDA Repulsed By Shire's Magnetic Promotion Of Vyvanse

DDMAC warning letter objects to a promotional magnet that obscures risk information; Bad Ad program draws attention to the tchotchke, which Shire stopped distributing in 2008.

Related Content

Topics

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel